应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GLPG Galapagos NV
休市中 11-22 16:00:00 EST
27.13
+1.91
+7.57%
盘后
27.13
+0.00
0.00%
17:11 EST
最高
27.15
最低
26.00
成交量
27.72万
今开
26.00
昨收
25.22
日振幅
4.56%
总市值
17.88亿
流通市值
12.08亿
总股本
6,590万
成交额
737.77万
换手率
0.62%
流通股本
4,454万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Galapagos Nv盘中异动 大幅拉升5.10%报26.51美元
市场透视 · 11-23 00:36
Galapagos Nv盘中异动 大幅拉升5.10%报26.51美元
异动解读 | Galapagos NV第三季度业绩低于预期 盘前股价重挫8%
异动解读 · 11-01
异动解读 | Galapagos NV第三季度业绩低于预期 盘前股价重挫8%
Galapagos Nv盘中异动 股价大跌6.40%
市场透视 · 10-31
Galapagos Nv盘中异动 股价大跌6.40%
异动解读 | Galapagos公司财报业绩低于预期 股价盘前大跌5%
异动解读 · 10-31
异动解读 | Galapagos公司财报业绩低于预期 股价盘前大跌5%
Galapagos NV 公布截至 9 月 30 日的季度业绩 - 收益摘要
Reuters · 10-31
Galapagos NV 公布截至 9 月 30 日的季度业绩 - 收益摘要
Galapagos NV 预计每股亏损 27 美分 - 财报前瞻
Reuters · 10-28
Galapagos NV 预计每股亏损 27 美分 - 财报前瞻
美国研究综述-加拉帕戈斯, 马什和麦克莱南, 旅行者
Reuters · 10-22
美国研究综述-加拉帕戈斯, 马什和麦克莱南, 旅行者
扭亏为盈无望,投资人等不下去了
生物制药小编 · 08-28
扭亏为盈无望,投资人等不下去了
异动解读 | Galapagos NV股价大涨5%,分析师下调目标价
异动解读 · 08-07
异动解读 | Galapagos NV股价大涨5%,分析师下调目标价
Galapagos Nv盘中异动 急速拉升5.05%报26.62美元
自选股智能写手 · 08-07
Galapagos Nv盘中异动 急速拉升5.05%报26.62美元
Galapagos NV:雷蒙德詹姆斯将评级下调至市场表现从超额表现。
智通财经 · 08-05
Galapagos NV:雷蒙德詹姆斯将评级下调至市场表现从超额表现。
Galapagos Nv盘中异动 临近收盘急速跳水5.13%报25.51美元
自选股智能写手 · 08-03
Galapagos Nv盘中异动 临近收盘急速跳水5.13%报25.51美元
Galapagos NV: RBC将目标价从35美元下调至32美元。
智通财经 · 08-02
Galapagos NV: RBC将目标价从35美元下调至32美元。
Galapagos NV 公布截至 6 月的季度业绩 - 收益摘要
Reuters · 08-02
Galapagos NV 公布截至 6 月的季度业绩 - 收益摘要
Galapagos NV 预计每股亏损 4 美分 - 财报前瞻
Reuters · 07-30
Galapagos NV 预计每股亏损 4 美分 - 财报前瞻
Reg-Galapagos和Adaptimmune签署临床合作协议并可选择独家许可Adaptimmune的Tcr T细胞候选疗法Uza-Cell用于头颈癌和潜在的未来实体瘤适应症
智通财经 · 05-31
Reg-Galapagos和Adaptimmune签署临床合作协议并可选择独家许可Adaptimmune的Tcr T细胞候选疗法Uza-Cell用于头颈癌和潜在的未来实体瘤适应症
加载更多
公司概况
公司名称:
Galapagos NV
所属市场:
NASDAQ
上市日期:
--
主营业务:
Galapagos Nv于1999年6月30日在比利时注册成立。该公司是一家综合性生物制药公司,致力于发现、开发和商业化具有新作用模式的药物,其中一些药物目前正处于多种疾病的临床开发中,具有高度未满足的医疗需求。他们专门研究和开发基于在人类原代细胞中发现和验证的新靶点的药物。
发行价格:
--
{"stockData":{"symbol":"GLPG","market":"US","secType":"STK","nameCN":"Galapagos NV","latestPrice":27.13,"timestamp":1732309200000,"preClose":25.22,"halted":0,"volume":277222,"hourTrading":{"tag":"盘后","latestPrice":27.13,"preClose":27.13,"latestTime":"17:11 EST","volume":134,"amount":3641.66,"timestamp":1732313462359},"delay":0,"floatShares":44543909,"shares":65897071,"eps":3.497319,"marketStatus":"休市中","marketStatusCode":7,"change":1.91,"latestTime":"11-22 16:00:00 EST","open":26,"high":27.15,"low":26,"amount":7377738.471531999,"amplitude":0.045599,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.497319,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":1,"listingDate":1431576000000,"adjPreClose":25.22,"adrRate":1,"preHourTrading":{"tag":"盘前","latestPrice":26.11,"preClose":25.22,"latestTime":"09:28 EST","volume":16316,"amount":424583.811588,"timestamp":1732285680424},"postHourTrading":{"tag":"盘后","latestPrice":27.13,"preClose":27.13,"latestTime":"17:11 EST","volume":134,"amount":3641.66,"timestamp":1732313462359},"volumeRatio":0.6740006643859764,"impliedVol":0.3788,"impliedVolPercentile":0.5595},"requestUrl":"/m/hq/s/GLPG","defaultTab":"news","newsList":[{"id":"2485295791","title":"Galapagos Nv盘中异动 大幅拉升5.10%报26.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485295791","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485295791?lang=zh_cn&edition=full","pubTime":"2024-11-23 00:36","pubTimestamp":1732293398,"startTime":"0","endTime":"0","summary":"北京时间2024年11月23日00时36分,Galapagos Nv股票出现波动,股价急速上涨5.10%。截至发稿,该股报26.51美元/股,成交量10.2795万股,换手率0.16%,振幅1.82%。Galapagos Nv股票所在的生物技术行业中,整体涨幅为0.73%。Galapagos Nv公司简介:Galapagos NV是一家完全一体化的生物技术公司,专注于药物的发掘、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123003638abd7c5f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123003638abd7c5f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLPG"],"gpt_icon":0},{"id":"1139853534","title":"异动解读 | Galapagos NV第三季度业绩低于预期 盘前股价重挫8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139853534","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139853534?lang=zh_cn&edition=full","pubTime":"2024-11-01 01:32","pubTimestamp":1730395975,"startTime":"0","endTime":"0","summary":"比利时生物科技公司Galapagos NV今日盘前大跌8.04%,报收36.4欧元,引发市场关注。从财报数据来看,这种股价重挫或受到公司最新季度业绩大幅低于市场预期的影响。在最新公布的2024年第三季度财报中,Galapagos公司调整后每股亏损77美分,远高于分析师此前平均预期的49美分亏损。显然,本季度业绩疲弱和利润前景堪忧令该公司在投资者心中形象大打折扣,加上资金外流,导致其股价在盘前遭遇重挫。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GLPG"],"gpt_icon":0},{"id":"2479080227","title":"Galapagos Nv盘中异动 股价大跌6.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479080227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479080227?lang=zh_cn&edition=full","pubTime":"2024-10-31 21:32","pubTimestamp":1730381561,"startTime":"0","endTime":"0","summary":"北京时间2024年10月31日21时32分,Galapagos Nv股票出现异动,股价大幅下跌6.40%。截至发稿,该股报26.76美元/股,成交量8.6721万股,换手率0.13%,振幅0.91%。Galapagos Nv股票所在的生物技术行业中,整体跌幅为1.85%。Galapagos Nv公司简介:Galapagos NV是一家完全一体化的生物技术公司,专注于药物的发掘、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121324195bd9c2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103121324195bd9c2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLPG"],"gpt_icon":0},{"id":"1156858224","title":"异动解读 | Galapagos公司财报业绩低于预期 股价盘前大跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156858224","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156858224?lang=zh_cn&edition=full","pubTime":"2024-10-31 16:12","pubTimestamp":1730362342,"startTime":"0","endTime":"0","summary":"比利时生物科技公司Galapagos NV今日盘前大跌5.04%,报收36.4欧元。此前,Galapagos公司公布了截至9月30日的最新季度财报,业绩数据低于市场预期,这被视为导致公司股价下跌的主要原因。财报显示,Galapagos本季度调整后每股亏损77美分,而分析师此前平均预期为亏损49美分。同时,过去三个月来,分析师对Galapagos未来盈利的平均预测下降了约155.7%,显示外界对公司前景信心不足。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GLPG"],"gpt_icon":0},{"id":"2479711305","title":"Galapagos NV 公布截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2479711305","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479711305?lang=zh_cn&edition=full","pubTime":"2024-10-31 10:31","pubTimestamp":1730341904,"startTime":"0","endTime":"0","summary":" * Galapagos NV 报告,截至9月30日的季度调整后每股亏损77美分,低于去年同期的每股收益39美分。* 营收同比下降 50.1%,至 5985 万欧元;分析师预期为 6944 万欧元。* Galapagos NV 公布的本季度每股收益为亏损 77 美分。* 该公司当季亏损 5043 万美元。华尔街对 Galapagos NV 的 12 个月目标价中位数为 37.50 欧元。本摘要由 LSEG 数据于 10 月 31 日 02:31 a.m. UTC 机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Galapagos NV 公布截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLPG"],"gpt_icon":0},{"id":"2478882984","title":"Galapagos NV 预计每股亏损 27 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2478882984","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478882984?lang=zh_cn&edition=full","pubTime":"2024-10-28 21:02","pubTimestamp":1730120559,"startTime":"0","endTime":"0","summary":" * Galapagos NV 将于10月30日公布截至2001年1月1日的业绩报告,预计该公司的季度收入将有所下降。* 根据 5 位分析师基于 LSEG 数据的平均估计,这家总部位于马林斯 安特卫普的公司预计收入将从去年同期的 1.2003 亿美元下降 41.8%,至 6979.6 万美元。* LSEG 的分析师平均预计 Galapagos NV 每股亏损 27 美分。* 华尔街对 Galapagos NV 的 12 个月目标价中位数为 32.00 美元,高于其最新收盘价 28.95 美元。10月28日 - 以前的季度业绩。除非另有说明,否则所有数据均以欧元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Galapagos NV 预计每股亏损 27 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLPG"],"gpt_icon":0},{"id":"2477463872","title":"美国研究综述-加拉帕戈斯, 马什和麦克莱南, 旅行者","url":"https://stock-news.laohu8.com/highlight/detail?id=2477463872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477463872?lang=zh_cn&edition=full","pubTime":"2024-10-22 14:31","pubTimestamp":1729578683,"startTime":"0","endTime":"0","summary":" 路透10月22日 - 华尔街证券分析师周二调整了对 Galapagos、Marsh & Mclennan 和 Travelers 等多家美国上市公司的评级和目标价。* Applovin Corp :摩根大通将目标价从57美元上调至160美元 * BCB Bancorp Inc :KBW 将目标价从 13.25 美元上调至 13.5 美元 * Contineum Therapeutics Inc :贝雅将其评级定为 \"跑赢大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRMW","PLXS","ETSY","BCBP","LU0943347566.SGD","MDLZ","ZETA","BK4085","LU0149725797.USD","MMC","LU","NSP","WRB","FITB","LU0820561818.USD","TTWO","VSEC","PPG","ENVX","LU0738911758.USD","SG9999015986.USD","DTE","MCBS","GRDN","LU0882574139.USD","LU1244550494.USD","BK4023","LU1244550221.USD","LU0971096721.USD","LU1720051017.SGD","LU0949170772.SGD","RBLX","ZION","CTNM","LU0061475181.USD","LU0316494557.USD","GLPG","APP","BK4559","TRV","IE00BJTD4N35.SGD","LU1003077747.HKD","BK4547","IE00BFMHRM44.USD","LU2023250330.USD","GXO","KMI","LU0211328371.USD"],"gpt_icon":1},{"id":"2462176441","title":"扭亏为盈无望,投资人等不下去了","url":"https://stock-news.laohu8.com/highlight/detail?id=2462176441","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462176441?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:20","pubTimestamp":1724808017,"startTime":"0","endTime":"0","summary":"近日,由知名生物技术投资者Oleg Nodelman管理的生物技术对冲基金Ecor1 Capital已将其在比利时制药商Galapagos NV的持股比例增至9.9%,在这家制药商长期经营困难的背景下,此举表明Nodelman可能想要干预公司决策。2019年时,吉利德和Galapagos达成了关于JAK1抑制剂filgotinib的合作协议,首付款高达7.25亿美元。导致临床暂停的原因是一名患者出现了帕金森综合症,受到这一消息影响,Galapagos公司的股价截止8月2日收盘下降了约5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408280926079f5feed4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408280926079f5feed4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLPG","BK4139"],"gpt_icon":0},{"id":"1138014261","title":"异动解读 | Galapagos NV股价大涨5%,分析师下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1138014261","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138014261?lang=zh_cn&edition=full","pubTime":"2024-08-07 22:49","pubTimestamp":1723042150,"startTime":"0","endTime":"0","summary":"比利时生物技术公司Galapagos NV今日盘中股价大涨5.13%,报收于26.62美元。尽管该公司最新财报显示营收和净利润均有所增长,但导致股价大涨的主要原因可能与分析师的评级调整有关。据报道,摩根士丹利分析师维持了对Galapagos的\"持有\"评级,但将目标价从之前的35美元下调至32美元。不过,Galapagos作为一家专注于创新药物研发的生物科技公司,其产品管线和长期发展前景仍获得市场认可。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLPG"],"gpt_icon":0},{"id":"2457235840","title":"Galapagos Nv盘中异动 急速拉升5.05%报26.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457235840","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457235840?lang=zh_cn&edition=full","pubTime":"2024-08-07 22:44","pubTimestamp":1723041879,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日22时44分,Galapagos Nv股票出现异动,股价大幅拉升5.05%。截至发稿,该股报26.62美元/股,成交量3.223万股,换手率0.05%,振幅1.30%。Galapagos Nv股票所在的生物技术行业中,整体跌幅为1.37%。Galapagos Nv公司简介:Galapagos NV是一家完全一体化的生物技术公司,专注于药物的发掘、开发和商业化。消息层面,截至22时44分,《摩根士丹利维持Galapagos持有评级,下调目标价至32美元》资讯为影响Galapagos Nv的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807224439941ff11f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807224439941ff11f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLPG"],"gpt_icon":0},{"id":"2457679780","title":"Galapagos NV:雷蒙德詹姆斯将评级下调至市场表现从超额表现。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457679780","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457679780?lang=zh_cn&edition=full","pubTime":"2024-08-05 13:29","pubTimestamp":1722835750,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GLPG","BK4139"],"gpt_icon":0},{"id":"2456257599","title":"Galapagos Nv盘中异动 临近收盘急速跳水5.13%报25.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456257599","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456257599?lang=zh_cn&edition=full","pubTime":"2024-08-03 03:54","pubTimestamp":1722628467,"startTime":"0","endTime":"0","summary":"北京时间2024年08月03日03时54分,Galapagos Nv股票出现波动,股价急速下跌5.13%。截至发稿,该股报25.51美元/股,成交量31.041万股,换手率0.47%,振幅3.79%。Galapagos Nv股票所在的生物技术行业中,整体跌幅为1.56%。Galapagos Nv公司简介:Galapagos NV是一家完全一体化的生物技术公司,专注于药物的发掘、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240803035427aefcfec6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240803035427aefcfec6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLPG","BK4139"],"gpt_icon":0},{"id":"2456317236","title":"Galapagos NV: RBC将目标价从35美元下调至32美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456317236","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456317236?lang=zh_cn&edition=full","pubTime":"2024-08-02 23:09","pubTimestamp":1722611364,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","GLPG"],"gpt_icon":0},{"id":"2456249387","title":"Galapagos NV 公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2456249387","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456249387?lang=zh_cn&edition=full","pubTime":"2024-08-02 05:51","pubTimestamp":1722549086,"startTime":"0","endTime":"0","summary":" * Galapagos NV 报告,在截至6月底的季度里,该公司调整后每股收益为14美分,高于去年同期的每股收益8美分。分析师对该季度的唯一预测是每股亏损 21 美分。* 营收同比下降 48.1%,为 7787 万欧元;分析师预期为 7888 万欧元。* Galapagos NV 公布的本季度每股收益为 14 美分。8月1日 - 预测变化 * 在过去三个月中,分析师的平均收益预期没有变化。华尔街对 Galapagos NV 的 12 个月目标价中位数为 37.50 欧元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLPG"],"gpt_icon":0},{"id":"2455093004","title":"Galapagos NV 预计每股亏损 4 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455093004","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455093004?lang=zh_cn&edition=full","pubTime":"2024-07-30 21:52","pubTimestamp":1722347529,"startTime":"0","endTime":"0","summary":" * Galapagos NV 将于8月1日公布截至2024年6月30日的季度业绩,预计该公司的季度收入将有所下降。* 根据 LSEG 数据,2 位分析师的平均预期显示,这家总部位于马林斯 安特卫普的公司预计营收将从去年同期的 1.4995 亿欧元下降 56.8%,至 6475 万欧元。* LSEG 的分析师平均预计 Galapagos NV 每股亏损 4 美分。* 华尔街对 Galapagos NV 的 12 个月目标价中位数为 35.00 美元,高于其最新收盘价 27.65 美元。7月30日 - 以前的季度业绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLPG"],"gpt_icon":0},{"id":"2439667702","title":"Reg-Galapagos和Adaptimmune签署临床合作协议并可选择独家许可Adaptimmune的Tcr T细胞候选疗法Uza-Cell用于头颈癌和潜在的未来实体瘤适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2439667702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439667702?lang=zh_cn&edition=full","pubTime":"2024-05-31 04:06","pubTimestamp":1717099579,"startTime":"0","endTime":"0","summary":"Reg-Galapagos和Adaptimmune签署临床合作协议并可选择独家许可Adaptimmune的Tcr T细胞候选疗法Uza-Cell用于头颈癌和潜在的未来实体瘤适应症","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405310406199f06ff03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405310406199f06ff03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLPG","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.glpg.com","stockEarnings":[{"period":"1week","weight":0.0123},{"period":"1month","weight":-0.0951},{"period":"3month","weight":0.0479},{"period":"6month","weight":-0.0051},{"period":"1year","weight":-0.267},{"period":"ytd","weight":-0.3326}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Galapagos Nv于1999年6月30日在比利时注册成立。该公司是一家综合性生物制药公司,致力于发现、开发和商业化具有新作用模式的药物,其中一些药物目前正处于多种疾病的临床开发中,具有高度未满足的医疗需求。他们专门研究和开发基于在人类原代细胞中发现和验证的新靶点的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.049676},{"month":2,"riseRate":0.111111,"avgChangeRate":-0.082263},{"month":3,"riseRate":0.444444,"avgChangeRate":0.016596},{"month":4,"riseRate":0.555556,"avgChangeRate":-0.008218},{"month":5,"riseRate":0.333333,"avgChangeRate":0.026988},{"month":6,"riseRate":0.2,"avgChangeRate":-0.040507},{"month":7,"riseRate":0.6,"avgChangeRate":0.058461},{"month":8,"riseRate":0.2,"avgChangeRate":-0.029141},{"month":9,"riseRate":0.4,"avgChangeRate":-0.030767},{"month":10,"riseRate":0.4,"avgChangeRate":-0.002427},{"month":11,"riseRate":0.5,"avgChangeRate":-0.005141},{"month":12,"riseRate":0.777778,"avgChangeRate":0.058321}],"exchange":"NASDAQ","name":"Galapagos NV","nameEN":"Galapagos NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Galapagos NV(GLPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Galapagos NV(GLPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Galapagos NV,GLPG,Galapagos NV股票,Galapagos NV股票老虎,Galapagos NV股票老虎国际,Galapagos NV行情,Galapagos NV股票行情,Galapagos NV股价,Galapagos NV股市,Galapagos NV股票价格,Galapagos NV股票交易,Galapagos NV股票购买,Galapagos NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Galapagos NV(GLPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Galapagos NV(GLPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}